A double-blind, randomised, placebo-controlled, parallel-group, multicentre, phase III study to assess the impact of rosuvastatin treatment for 26 weeks (titrated to a maximum dose of 40mg once daily) on left ventricular function, cytokines and lipid parameters in patients with established systolic chronic heart failure.

Trial Profile

A double-blind, randomised, placebo-controlled, parallel-group, multicentre, phase III study to assess the impact of rosuvastatin treatment for 26 weeks (titrated to a maximum dose of 40mg once daily) on left ventricular function, cytokines and lipid parameters in patients with established systolic chronic heart failure.

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Nov 2010

At a glance

  • Drugs Rosuvastatin (Primary)
  • Indications Chronic heart failure
  • Focus Pharmacodynamics
  • Sponsors AstraZeneca
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 10 Sep 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top